Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

This study is testing a four-drug combination — daratumumab, carfilzomib, pomalidomide, and dexamethasone — for patients with multiple myeloma (a blood cancer) that has come back or stopped responding to treatment. **You may be eligible if...** - You are 18–80 years old - You have been diagnosed with multiple myeloma that has relapsed (come back) or is refractory (no longer responding to treatment) - You have previously received certain standard treatments for myeloma - Your blood counts and organ function meet study requirements **You may NOT be eligible if...** - You have not yet been treated for myeloma (this trial is for relapsed/refractory disease) - You have severe heart disease or uncontrolled infections - You are pregnant or breastfeeding - You have a history of severe allergic reactions to any of the study drugs Talk to your doctor to see if this trial is right for you.